First patient dosed in Phase 1b randomized, placebo-controlled study evaluating safety, tolerability and weight loss over 12 weeks Market research indicates strong demand for ketogenic-metabolic approaches, including among adults with obesity who are not currently receiving treatment BL-001 positioned as a potential oral ketogenic-metabolic therapy designed for gradual, sustained weight loss with improved tolerability Feb. 24, 2026 -- Bloom Science, Inc., a clinical-stage biotech company focuse

Gilead Sciences has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval. Arcellx partnered with Gilead to develop the BCMA-directed CAR-T anitocabtagene autoleucel (anito-cel) in 2022. Gilead invested in Arcellx as part of the agreement and, having invested again when amending the deal in 2023, owns 11.5% of the company. With Gilead on the hook for $530 million in milestones for anito-cel, analysts had speculated about a pot

Looking to redeem its IL-17A/F nanobody after a mixed showing in hidradenitis suppurativa (HS) last year, MoonLake Immunotherapeutics unveiled Phase II data Monday for sonelokimab that it believes could change the treatment paradigm in axial spondyloarthritis (axSpA). The 12-week S-OLARIS study enrolled patients with both the radiographic and non-radiographic forms of the chronic inflammatory spine disease. According to topline results, 81% of treated patients (n=26) achieved at least a 40% imp

Feb. 24, 2026 -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", SEHK: 1877.HK; SSE: 688180). Under the collaborati

Feb. 23, 2026 -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports. The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Com

The first two China-to-West licensing deals of the Chinese New Year have landed. GSK will again return to the world’s most bustling biopharma dealmaking region with a two-siRNA pact with Frontier Biotechnologies for undisclosed immunological diseases. Meanwhile, a new UK and US biotech called Solstice Oncology has been formed around an anti-CTLA-4 asset from Harbour BioMed, a multinational biotech that has done deals with AstraZeneca and a handful of other drugmakers. Each deal could be worth

Feb. 23, 2026 -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele (PiZZ). TSRA-196 is designed to pr

Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood Feb. 23, 2026 -- Bracco, a global leader in diagnostic imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the current VUEWAY® (gadopiclenol) solution for injection, intravenous use, for use in neonates and infants. VUEWAY® injection is a macrocyclic gadolinium-based contrast a

February 23, 2026 -- Vidac Pharma Holdings Plc. announces that the first patient has been successfully enrolled and dosed in its Phase 2b clinical study evaluating VDA-1102 for the treatment of highly proliferative lesions of Actinic Keratosis (AK). The initiation of patient dosing follows completion of applicable regulatory requirements, importation of the investigational medicinal product, and training of the medical team at Centroderm GmbH (Wuppertal, Germany). This milestone marks an import

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK. This approval is based on the GEMSTONE-301 study, a multicenter, randomized, double-blind Phase III trial. Results demonstrated that sugemalimab provided statistically significant improvement in progression-